查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1798907

全球HER2乳癌检测市场

HER2 Breast Cancer Tests
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 268 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球 HER2乳癌检测市场规模将达到 5.295 亿美元

全球HER2乳癌检测市场规模预计在2024年为3.944亿美元，到2030年将达到5.295亿美元，在2024-2030年的分析期内，复合年增长率为5.0%。免疫组织化学检测是本报告分析的细分领域之一，预计其复合年增长率为4.0%，到分析期结束时将达到3.313亿美元。萤光/显色原位杂合反应检测细分领域在分析期间的复合年增长率预计为6.8%。

美国市场规模估计为 1.074 亿美元，中国市场预计复合年增长率为 7.8%

美国HER2乳癌检测市场规模预计在 2024 年达到 1.074 亿美元。作为世界第二大经济体，中国预计到 2030 年市场规模将达到 1.041 亿美元，在 2024-2030 年的分析期内，复合年增长率为 7.8%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为 2.5% 和 5.0%。在欧洲，预计德国的复合年增长率为 3.2%。

全球 HER2乳癌检测市场 - 主要趋势与驱动因素摘要

为什么 HER2乳癌检测在现代肿瘤学中至关重要？

HER2（人类表皮生长因子受体2）乳癌检测是一种诊断程序，用于确定乳癌组织中HER2基因的过度表现或扩增。这些检测对于确定治疗策略至关重要，因为HER2阳性的癌症通常生长得更快，对标靶治疗的反应也不同。准确的识别有助于选择合适的治疗方法，例如曲妥珠单抗和Pertuzumab，特异性抑制HER2活性并改善生存结局。

检测通常使用免疫组织化学 (IHC) 或原位杂合反应(ISH) 技术对切片检查或手术组织样本进行。近年来，先进的检测方法、数位病理学解决方案和伴随诊断技术应运而生，以提高诊断准确性。 HER2 检测现已成为肿瘤中心乳癌诊断的常规组成部分，这促使对高品质、可靠诊断平台的需求日益增长。

哪些诊断创新影响了检测的准确性和采用率？

技术进步提高了 HER2 检测的灵敏度、可重复性和可解释性。免疫组化 (IHC) 检测也不断发展，包括抗体增强、自动化染色系统和标准化评分演算法。双探针原位杂交 (ISH) 检测可在可疑病例中提供确认，并有助于解决临界 HER2 表达问题。萤光杂交 (FISH) 和显色原位杂交 (CISH) 被广泛用于在细胞层面确认基因扩增。

新的平台正在整合数位成像、人工智慧辅助病理学和多重检测功能，以增强诊断工作流程。一些 HER2 检测正在开发中，作为更广泛的基因组分析检测的一部分，这些检测可同时评估多种生物标记。与标靶药物共同开发的伴随诊断检测也越来越受欢迎，尤其是在 HER2 标靶疗法扩展到其他癌症类型（例如胃癌和大肠癌）的情况下。

哪些地方的测试量在增加？哪些设施在推动这项成长？

乳癌发生率的上升以及肿瘤学中个人化医疗的日益普及，推动了全球检测量的增加。医院、专科癌症中心和参考实验室是主要的检测场所。在高所得国家，HER2 检测是乳癌筛检的标准项目；而在中等收入地区，由于病理基础设施和治疗可近性的改善，人们对 HER2 检测的兴趣日益浓厚。

北美和欧洲是成熟的市场，拥有完善的诊断指南和报销系统。亚太地区正经历快速成长，这得益于人们对乳癌的认识不断提高、标靶治疗的可及性不断扩大以及政府支持癌症诊断的倡议。官民合作关係和国家癌症筛检计画的发展进一步加速了检测的普及。

是什么推动了 HER2乳癌检测市场的成长？

HER2乳癌检测市场的成长受到多种因素的推动，包括全球乳癌发生率的上升、HER2标靶治疗药物的使用增加以及诊断准确性的持续提高。染色试剂、自动化系统和人工智慧病理学工具的进步正在提高HER2检测的准确性和扩充性。

癌症医院、病理实验室以及新型 HER2 标靶药物伴随诊断的终端应用不断扩展，正在提升市场的重要性。监管机构核准在乳癌以外的肿瘤类型中进行 HER2 检测，以及多重生物标记检测的日益普及，正在拓宽其应用范围。随着精准医疗在肿瘤治疗中的重要性日益凸显，对可靠、高通量 HER2 检测解决方案的需求预计将稳定成长。

部分

检测类型（免疫组织化学、萤光/显色原位杂合反应）；最终用户（医院最终用户、诊断实验室最终用户）

受访公司范例

  • Abbott Laboratories
  • Abnova Corporation
  • Agilent Technologies
  • Bio-Genex Laboratories
  • Beckman Coulter（Danaher）
  • Becton, Dickinson and Company（BD）
  • EKF Diagnostics
  • Hologic, Inc.
  • Leica Biosystems（Danaher）
  • Meridian Bioscience
  • Olympus Corporation
  • Oxford Gene Technology（Sysmex）
  • QIAGEN NV
  • REVEAL Genomics SL
  • Roche Diagnostics（F. Hoffmann-La Roche）
  • Thermo Fisher Scientific
  • Veracyte, Inc.
  • NeoGenomics Laboratories, Inc.
  • Empire Genomics/Biocare Medical
  • Applied Spectral Imaging

人工智慧集成

我们正在利用有效的专家内容和人工智慧工具来改变市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP38902

Global HER2 Breast Cancer Tests Market to Reach US$529.5 Million by 2030

The global market for HER2 Breast Cancer Tests estimated at US$394.4 Million in the year 2024, is expected to reach US$529.5 Million by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Immunohistochemistry Test, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$331.3 Million by the end of the analysis period. Growth in the Fluorescence / Chromogenic In-Situ Hybridization Test segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$107.4 Million While China is Forecast to Grow at 7.8% CAGR

The HER2 Breast Cancer Tests market in the U.S. is estimated at US$107.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$104.1 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global HER2 Breast Cancer Tests Market - Key Trends & Drivers Summarized

Why Are HER2 Breast Cancer Tests Essential in Modern Oncology?

HER2 (Human Epidermal Growth Factor Receptor 2) breast cancer tests are diagnostic procedures used to determine the overexpression or amplification of the HER2 gene in breast cancer tissue. These tests are critical in guiding treatment decisions, as HER2-positive cancers typically grow faster and respond differently to targeted therapies. Accurate identification allows for the selection of therapies such as trastuzumab or pertuzumab, which specifically inhibit HER2 activity and improve survival outcomes.

Testing is typically performed using immunohistochemistry (IHC) or in situ hybridization (ISH) techniques on biopsy or surgical tissue samples. In recent years, advanced assays, digital pathology solutions, and companion diagnostics have emerged to improve diagnostic precision. HER2 testing is now a routine part of breast cancer diagnosis in oncology centers, contributing to the growing demand for high-quality and reliable diagnostic platforms.

What Diagnostic Innovations Are Influencing Test Accuracy and Adoption?

Technological advancements have improved HER2 test sensitivity, reproducibility, and interpretability. IHC tests have evolved with enhanced antibodies, automated staining systems, and standardized scoring algorithms. Dual-probe ISH tests provide confirmation in ambiguous cases, helping resolve borderline HER2 expressions. Fluorescence ISH (FISH) and chromogenic ISH (CISH) remain widely used for confirming gene amplification at the cellular level.

Emerging platforms are integrating digital imaging, AI-assisted pathology, and multiplex testing capabilities to enhance diagnostic workflows. Some HER2 assays are now being developed as part of broader genomic profiling tests that assess multiple biomarkers simultaneously. Companion diagnostic tests co-developed with targeted drugs are also gaining traction, especially as HER2-targeted treatments expand into other tumor types like gastric and colorectal cancers.

Where Is Testing Volume Increasing, and Which Institutions Are Driving Uptake?

Testing volumes are rising globally due to increasing breast cancer incidence and the growing adoption of personalized medicine in oncology. Hospitals, cancer specialty centers, and reference laboratories are key testing sites. In high-income countries, HER2 testing is a standard part of breast cancer workups, while in middle-income regions, uptake is increasing with improvements in pathology infrastructure and treatment access.

North America and Europe are mature markets with well-established diagnostic guidelines and reimbursement systems. Asia Pacific is witnessing rapid growth due to rising breast cancer awareness, expanding access to targeted therapies, and government initiatives supporting oncology diagnostics. The development of public-private partnerships and national cancer screening programs is further accelerating testing penetration.

What Is Driving Growth in the HER2 Breast Cancer Tests Market?

Growth in the HER2 breast cancer tests market is driven by several factors including rising global breast cancer incidence, increased use of HER2-targeted therapies, and ongoing improvements in diagnostic precision. Advances in staining reagents, automation systems, and AI-powered pathology tools are making HER2 testing more accurate and scalable.

End-use expansion in oncology hospitals, pathology labs, and companion diagnostics for new HER2-targeted drugs is boosting market relevance. Regulatory approvals for HER2 testing in tumor types beyond breast cancer and increased adoption of multiplex biomarker panels are broadening application scope. As precision medicine becomes central to oncology care, demand for reliable, high-throughput HER2 testing solutions is expected to grow steadily.

SCOPE OF STUDY:

The report analyzes the HER2 Breast Cancer Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Immunohistochemistry Test, Fluorescence / Chromogenic In-Situ Hybridization Test); End-User (Hospitals End-User, Diagnostic Laboratories End-User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • Abbott Laboratories
  • Abnova Corporation
  • Agilent Technologies
  • Bio-Genex Laboratories
  • Beckman Coulter (Danaher)
  • Becton, Dickinson and Company (BD)
  • EKF Diagnostics
  • Hologic, Inc.
  • Leica Biosystems (Danaher)
  • Meridian Bioscience
  • Olympus Corporation
  • Oxford Gene Technology (Sysmex)
  • QIAGEN N.V.
  • REVEAL Genomics S.L.
  • Roche Diagnostics (F. Hoffmann-La Roche)
  • Thermo Fisher Scientific
  • Veracyte, Inc.
  • NeoGenomics Laboratories, Inc.
  • Empire Genomics / Biocare Medical
  • Applied Spectral Imaging

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • HER2 Breast Cancer Tests - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Breast Cancer Drives Consistent Demand for HER2 Status Testing in Oncology Diagnostics
    • Increased Adoption of Targeted Therapy Approaches Strengthens Business Case for Routine HER2 Screening
    • Growing Use of HER2 Tests in Treatment Stratification Spurs Integration into First-Line Diagnostic Protocols
    • Expansion of Companion Diagnostics for HER2-Targeted Drugs Throws Spotlight on Precision Testing Technologies
    • Regulatory Approvals for HER2-Positive Therapies Boost Clinical Need for Accurate and Standardized HER2 Testing
    • Adoption of FISH, IHC, and Dual ISH Techniques Enables Multi-Modality Testing Options in Oncology Labs
    • Rising Healthcare Access and Diagnostic Infrastructure in Emerging Markets Enhances HER2 Test Availability
    • Growth in Breast Cancer Screening Programs Supports Early Detection and HER2-Based Prognostic Evaluation
    • Increasing Use of Biopsy and Cytology Samples in HER2 Testing Expands Test Adoption Across Specimen Types
    • Integration of HER2 Testing in Comprehensive Genomic Panels Propels Use in Broader Molecular Oncology Workflows
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World HER2 Breast Cancer Tests Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for HER2 Breast Cancer Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Immunohistochemistry Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Fluorescence / Chromogenic In-Situ Hybridization Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Fluorescence / Chromogenic In-Situ Hybridization Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Fluorescence / Chromogenic In-Situ Hybridization Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Laboratories End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostic Laboratories End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • JAPAN
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • CHINA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • EUROPE
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for HER2 Breast Cancer Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • FRANCE
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • GERMANY
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for HER2 Breast Cancer Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • INDIA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for HER2 Breast Cancer Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for HER2 Breast Cancer Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • AFRICA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030

IV. COMPETITION